Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Total Current Liabilities: 2009-2024

Historic Total Current Liabilities for Cytokinetics (CYTK) over the last 15 years, with Dec 2024 value amounting to $179.7 million.

  • Cytokinetics' Total Current Liabilities rose 29.44% to $142.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $142.1 million, marking a year-over-year increase of 29.44%. This contributed to the annual value of $179.7 million for FY2024, which is 74.99% up from last year.
  • As of FY2024, Cytokinetics' Total Current Liabilities stood at $179.7 million, which was up 74.99% from $102.7 million recorded in FY2023.
  • Cytokinetics' 5-year Total Current Liabilities high stood at $179.7 million for FY2024, and its period low was $31.2 million during FY2020.
  • Moreover, its 3-year median value for Total Current Liabilities was $102.7 million (2023), whereas its average is $122.3 million.
  • Data for Cytokinetics' Total Current Liabilities shows a peak YoY surged of 130.33% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Cytokinetics' Total Current Liabilities stood at $31.2 million in 2020, then skyrocketed by 130.33% to $71.9 million in 2021, then increased by 17.75% to $84.6 million in 2022, then rose by 21.34% to $102.7 million in 2023, then surged by 74.99% to $179.7 million in 2024.